Explore more publications!

Latest News

Labels On
FILTER THE FEED
Left-wing Center-left Neutral Public Broadcaster Gov't Institution Center-right Right-wing Pro-Government Gov't Propaganda Indeterminate
FILTER THE FEED
Source Label Filters

All labels are selected. Deselect any labels you want to hide from your feed.

Labels:

Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
Column: Next step for AI is in the area of human resources

Column: Next step for AI is in the area of human resources

<![CDATA[Aromatase Inhibitors Favored as Adjuvant ET in HR+/HER2+ Early Breast Cancer]]>

<![CDATA[Aromatase Inhibitors Favored as Adjuvant ET in HR+/HER2+ Early Breast Cancer]]>

<![CDATA[ASCENT-07: Sacituzumab PFS Not Significant vs Chemo in HR+/HER2- BC]]>

<![CDATA[ASCENT-07: Sacituzumab PFS Not Significant vs Chemo in HR+/HER2- BC]]>

American Fintech Council Supports House Legislation on Artificial Intelligence and Financial Services

American Fintech Council Supports House Legislation on Artificial Intelligence and Financial Services

<![CDATA[Sacituzumab Govitecan Fails to Reach Significant PFS in HR+/HER2– mBC]]>

<![CDATA[Sacituzumab Govitecan Fails to Reach Significant PFS in HR+/HER2– mBC]]>

<![CDATA[Adjuvant Aromatase Inhibition Is Associated With Improved DFS, TTDR in HR+/HER2+ Breast Cancer]]>

<![CDATA[Adjuvant Aromatase Inhibition Is Associated With Improved DFS, TTDR in HR+/HER2+ Breast Cancer]]>

<![CDATA[Sacituzumab Govitecan Fails to Meet Primary PFS End Point in First-Line HR+/HER2– mBC]]>

<![CDATA[Sacituzumab Govitecan Fails to Meet Primary PFS End Point in First-Line HR+/HER2– mBC]]>

November 2025: The New Priorities of European Tech Investing

November 2025: The New Priorities of European Tech Investing

<![CDATA[Sacituzumab Govitecan Does Not Meet Statistical Significance in HR+/HER2– mBC]]>

<![CDATA[Sacituzumab Govitecan Does Not Meet Statistical Significance in HR+/HER2– mBC]]>

Oral SERD giredestrant cuts recurrence risk 30% in early HR positive breast cancer

Oral SERD giredestrant cuts recurrence risk 30% in early HR positive breast cancer

Indeterminate Drug Discovery and Development
Owner: Mountaingate Capital
National Council ratifies BIMSTEC Convention on Mutual Legal Assistance in Criminal Matters

National Council ratifies BIMSTEC Convention on Mutual Legal Assistance in Criminal Matters

Pro-Government Bhutan Broadcasting Service (BBS)
Owner: Bhutan Government
Impact HR Consulting Limited acquires Tugela People

Impact HR Consulting Limited acquires Tugela People

Indeterminate Milton Keynes Citizen
Owner: Malcolm Denmark
Alcon appoints Anup Changavalli as Head of Human Resources for Australia and New Zealand

Alcon appoints Anup Changavalli as Head of Human Resources for Australia and New Zealand

Indeterminate ETHRWorld Southeast Asia
Owner: Sahu Jain Family
Column: Next step for AI is in the area of human resources

Column: Next step for AI is in the area of human resources

<![CDATA[Aromatase Inhibitors Favored as Adjuvant ET in HR+/HER2+ Early Breast Cancer]]>

<![CDATA[Aromatase Inhibitors Favored as Adjuvant ET in HR+/HER2+ Early Breast Cancer]]>

<![CDATA[ASCENT-07: Sacituzumab PFS Not Significant vs Chemo in HR+/HER2- BC]]>

<![CDATA[ASCENT-07: Sacituzumab PFS Not Significant vs Chemo in HR+/HER2- BC]]>

American Fintech Council Supports House Legislation on Artificial Intelligence and Financial Services

American Fintech Council Supports House Legislation on Artificial Intelligence and Financial Services

<![CDATA[Sacituzumab Govitecan Fails to Reach Significant PFS in HR+/HER2– mBC]]>

<![CDATA[Sacituzumab Govitecan Fails to Reach Significant PFS in HR+/HER2– mBC]]>

<![CDATA[Adjuvant Aromatase Inhibition Is Associated With Improved DFS, TTDR in HR+/HER2+ Breast Cancer]]>

<![CDATA[Adjuvant Aromatase Inhibition Is Associated With Improved DFS, TTDR in HR+/HER2+ Breast Cancer]]>

<![CDATA[Sacituzumab Govitecan Fails to Meet Primary PFS End Point in First-Line HR+/HER2– mBC]]>

<![CDATA[Sacituzumab Govitecan Fails to Meet Primary PFS End Point in First-Line HR+/HER2– mBC]]>

November 2025: The New Priorities of European Tech Investing

November 2025: The New Priorities of European Tech Investing

<![CDATA[Sacituzumab Govitecan Does Not Meet Statistical Significance in HR+/HER2– mBC]]>

<![CDATA[Sacituzumab Govitecan Does Not Meet Statistical Significance in HR+/HER2– mBC]]>

Oral SERD giredestrant cuts recurrence risk 30% in early HR positive breast cancer

Oral SERD giredestrant cuts recurrence risk 30% in early HR positive breast cancer

National Council ratifies BIMSTEC Convention on Mutual Legal Assistance in Criminal Matters

National Council ratifies BIMSTEC Convention on Mutual Legal Assistance in Criminal Matters

Impact HR Consulting Limited acquires Tugela People

Impact HR Consulting Limited acquires Tugela People

Alcon appoints Anup Changavalli as Head of Human Resources for Australia and New Zealand

Alcon appoints Anup Changavalli as Head of Human Resources for Australia and New Zealand

Show More

Video Stories

YouTube video thumbnail: A Conversation About Workplace Safety, Innovation and Sustainability With Laura Galli, 3M
Play
A Conversation About Workplace Safety, Innovation and Sustainability With Laura Galli, 3M
YouTube video thumbnail: AI Adoption on Wall Street Set to Drive Near-Term Hiring
Play
AI Adoption on Wall Street Set to Drive Near-Term Hiring
YouTube video thumbnail: Canadian Universities eye Global Researchers With Major Funding Boost
Play
Canadian Universities eye Global Researchers With Major Funding Boost
YouTube video thumbnail: 12 FBI Agents Fired for Kneeling During Protest sue to get Their Jobs Back
Play
12 FBI Agents Fired for Kneeling During Protest sue to get Their Jobs Back

Video Title

Press Releases

Show More
Your brand’s story is being written — with or without you.
We’re the leading press release service for mid-sized businesses & organizations built for the AI era.
Learn more

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions